Large drugmakers with the highest free cash flow yield

Ranked

44

of 412 large drugmakers we cover

Median

5.5%

Highest

26.9%

EBS

Range

0.2% to 26.9%

#	Company	FCF yield	PE	Revenue growth (TTM)	Market cap
1	EBSEmergent BioSolutions	26.9%	n/m	−9.6%	$319.4M
2	AKBAAkebia Therapeutics	25.6%	n/m	+7.5%	$157.1M
3	ORGOOrganogenesis	16.3%	n/m	+6.5%	$127.8M
4	AYTUAytu Biopharma	15.8%	n/m	−13.3%	$20.6M
5	OGNOrganon	15.7%	17.9×	−2.5%	$3.6B
6	AMPHAmphastar Pharmaceuticals	14.3%	14.8×	+1.0%	$1.1B
7	NRIXNurix Therapeutics	13.4%	11.0×	n/m	$2.8B
8	INVAInnoviva	12.7%	n/m	+18.8%	$1.5B
9	PCRXPacira BioSciences	12.4%	104×	+5.7%	$1.5B
10	JAZZJazz Pharmaceuticals	11.5%	14.6×	+12.6%	$13.9B
11	PBHPrestige Consumer Healthcare	10.4%	13.4×	−1.4%	$2.3B
12	ANIPANI Pharmaceuticals	10.4%	15.4×	+30.9%	$1.7B
13	BMYBristol-Myers Squibb	9.1%	13.5×	+3.1%	$125.6B
14	LFVNLifevantage	9.1%	14.7×	−20.1%	$73.4M
15	NATRNatures Sunshine Products	8.5%	12.0×	+6.8%	$213.8M
16	BIIBBiogen	7.3%	44.4×	+0.3%	$37B
17	PBYIPuma Biotechnology	7.2%	21.2×	−2.9%	$568.9M
18	BMRNBiomarin Pharmaceutical	6.8%	151×	+11.2%	$10.8B
19	GILDGilead Sciences	6.7%	n/m	+5.5%	$193.5B
20	PFEPfizer	6.4%	39.5×	−0.2%	$171.2B
21	ZVRAZevra Therapeutics	5.6%	10.5×	+119.4%	$582.6M
22	SEPNSepterna	5.6%	n/m	n/m	$1.9B
23	RMTIRockwell Medical	5.5%	n/m	−21.1%	$28M
24	PRGOPERRIGO	5.4%	n/m	−4.2%	$2.2B
25	MRKMerck	4.5%	116×	+4.6%	$358.4B
26	AMGNAmgen	4.3%	27.3×	+9.1%	$237.5B
27	ACADAcadia Pharmaceuticals	4.3%	n/m	+11.8%	$3.4B
28	LQDALiquidia	3.9%	30.7×	n/m	$3.8B
29	ABBVAbbVie	3.6%	80.7×	+10.4%	$504.8B
30	ELANElanco Animal Health	3.4%	n/m	+12.0%	$11.3B
31	KNSAKiniksa Pharmaceuticals International	3.1%	79.1×	+58.9%	$6B
32	ALKSAlkermes plc.	3.0%	115×	+10.8%	$7.3B
33	LGNDLigand Pharmaceuticals	2.2%	32.3×	+54.9%	$6.1B
34	AMRXAmneal Pharmaceuticals	2.0%	41.6×	+9.3%	$6.5B
35	LLYEli Lilly and	1.5%	42.7×	+49.6%	$1.2T
36	PTGXProtagonist Therapeutics	1.5%	134×	+34.8%	$9B
37	CORTCorcept Therapeutics	1.2%	204×	+16.0%	$9.3B
38	ETONEton Pharmaceuticals	1.0%	n/m	n/m	$1.4B
39	ARQTArcutis Biotherapeutics	1.0%	142×	+76.1%	$3.9B
40	SUPNSupernus Pharmaceuticals	0.8%	n/m	+24.9%	$2.4B
41	PAHCPhibro Animal Health	0.6%	15.9×	+17.1%	$1.6B
42	CPIXCumberland Pharmaceuticals	0.5%	n/m	−1.1%	$127.2M
43	HROWHarrow	0.5%	n/m	+21.1%	$1.1B
44	TGTXTG Therapeutics	0.2%	19.8×	+76.1%	$8.3B

Not ranked: 169 with no positive free cash flow, 111 with not a meaningful number, 3 with a yield above 40% (usually a one-off). 85 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.